MoonLake Immunotherapeutics

MLTX

Equity

ISIN KY61559X1045 / Valor 118139749

NASDAQ (2024-12-24)

USD 52.67+1.02%

MoonLake Immunotherapeutics
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory diseases. The company's primary asset is Sonelokimab, an investigational Nanobody® designed to target and treat inflammation more effectively. By leveraging advanced biotechnological approaches, MoonLake aims to improve patient outcomes in conditions characterized by chronic inflammation. The company is dedicated to advancing Sonelokimab through clinical trials to establish its efficacy and safety, positioning itself as a key player in the biopharmaceutical industry’s efforts to address unmet medical needs in inflammatory diseases.

Summarized from source with an LLMView SourceSector: Finance

Q1 2024 Revenue Details

MoonLake Immunotherapeutics reported a net loss of $13,975,521 for the first quarter of 2024, compared to a net loss of $7,887,389 in the previous quarter, indicating increased expenses primarily due to expanded research and development activities.

Research and Development Expenses

For the first quarter of 2024, MoonLake Immunotherapeutics's research and development expenses were $13,014,049, an increase from $8,097,794 in the last quarter of 2023. This rise reflects the company's ongoing investment in its clinical programs, including the development of sonelokimab.

General and Administrative Expenses

The general and administrative expenses for MoonLake Immunotherapeutics in the first quarter of 2024 were slightly lower at $6,806,440 compared to $6,931,096 in the previous quarter, showing a marginal decrease in administrative spending.

Liquidity and Financial Position

As of the end of the first quarter of 2024, MoonLake Immunotherapeutics reported having $547.1 million in cash, cash equivalents, and short-term marketable debt securities. This strong liquidity position is expected to support the company's operations and clinical trial activities through the end of 2026.

Comprehensive Loss and Shareholder Impact

MoonLake Immunotherapeutics's comprehensive loss for the first quarter of 2024 was $13,712,018, compared to a comprehensive loss of $8,921,082 in the previous quarter. The loss per share for controlling interests shareholders was $0.22, reflecting the increased operational costs and investment in research.

Summarized from source with an LLMView Source

Key figures

-12.4%1Y

%3Y

%5Y

Performance

49.9%1Y

96.7%3Y

96.7%5Y

Volatility